Seat No.:	Enrolment No.

GUJARAT TECHNOLOGICAL UNIVERSITY M.PHARM – SEMESTER -1 - EXAMINATION – WINTER - 2018

Date: 03/01/2019 Subject Code: MPA102T **Subject Name: Advanced Pharmaceutical Analysis** Time: 10:30 AM TO 01:30 PM Total Marks: 80 **Instructions:** 1. Attempt any five questions. 2. Make Suitable assumptions wherever necessary. 3. Figures to the right indicate full marks. Explain Selection of batches, sampling frequency, specifications and storage **Q.1** 06 condition with respect to stability testing protocols. Give a short note on handling of degradation product. 05 **(b)** Describe in brief the procedure to study stability of the natural products. 05 (c) **Q.2** Give a note on photo stability testing guidelines. (a) 06 Discuss various Potential Sources of Elemental Impurities. 05 **(b)** Give applications of Immunoassay in relation to quantification. (c) 05 Why it is important to control residual solvent? Classify residual solvents in Q.3 (a) 06 detail along with their limits and reporting levels. **(b)** Discuss HPTLC/HPLC finger printing interactions. 05 Describe method for separation of bound and unbound drug in Immunoassays. (c) 05 What is gene regulation? Explain principle and procedures of PCR studies for **Q.4** 06 (a) gene regulation. Give effects of impurities in new drug products in terms of degradation. **(b)** 05 Write biological tests and assays of Rabies Vaccine. (c) 05 Define immunoassay. Explain basic principle of IA and production of 06 Q.5(a) antibodies. Discuss ICH guidelines laid down for stability studies for biological products. **(b)** 05 What is oxytocin? Give principle and procedure for the bioassay of Oxytocin. 05 (c) Q. 6 Discuss the regulatory requirements and protocols for phyto-pharmaceuticals 06 (a) Classify impurities in API. And its effects on stability of sample. 05 **(b)** (c) Describe various factors which affect the stability of samples. 05 **Q.7** (a) Define impurity and give detail notes of quantification of impurities as per ICH **06** guideline. Give Safety Assessment of Elemental Impurities for Oral, Parenteral and **(b)** 05 Inhalation Routes of Administration. (c) Discuss in detail shelf life calculation and stability zones. 05
